Recipharm Secures €25 Million Contract with Daewoong Pharmaceutical

News   Nov 24, 2015

 
Recipharm Secures €25 Million Contract with Daewoong Pharmaceutical
 
 
 

RELATED ARTICLES

PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets

News

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.

READ MORE

Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in Texas

News

First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.

READ MORE

IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE Antibodies

News

The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE